2015, Volume 8, Issue 3, pp 297 – 304

Preliminary results of using ALAnerv® in subacute motor incomplete paraplegics

SCImago Journal & Country Rank

Issues

Special Issues

Authors and Affiliations

Correspondence to: RDI Assist. Ioana Andone MD, Postgrad. “Bagdasar-Arseni” Teaching Emergency Hospital, 10-12 Berceni Av., postal code: 041915, District 4, Bucharest, Romania, Phone: +4021 334 30 25/ 1002, Mobile phone: +40733 013 667, E-mail: ioanaandone11@yahoo.com

Abstract

Rationale: To assess whether using ALAnerv® contributes to improvements of outcomes obtained in post SCI patients.

Objective: A prospective controlled clinical survey also to evaluate the safety and efficacy of ALAnerv® (2cps/ day for 28 days) in motor incomplete (AIS/ Frankel C) paraplegic subacute patients.

Methods and results: 59 patients divided in study (treated with ALAnerv®) and control, groups. This survey’s follow-up duration was of 28 days. Most of the studied patients were mid-aged (mean 43.75 years old) and respectively, men (64,29% in the study group; 58,06% in controls). We used descriptive statistics (functions: minimum, maximum, mean, median, standard deviation) and for related comparisons, parametric (Student t) and non-parametric (Mann-Whitney, Fisher’s exact, chi-square) tests.

The primary end-point: AIS motor values’ evolution (P= 0.015 – Mann-Whitney), showed that patients treated with ALAnerv® – vs. controls – had a statistically significant better increase of such scores at discharge. Paraclinical parameters, mainly exploring systemic inflammatory status (secondary end-point): ESR dynamics (P=0.13) had no statistical significance; the plasma leucocytes number (P=0.018), the neutrophils’ percentage (P=0.001) and fibrinogenemia (P= 0,017) proved in the treated group to have a statistically significant better evolution. We used “Statistical Package for Social Sciences” (SPSS).

Discussion: As there is actually no effective curative solution for the devastating pathology following SCI, any medical approach susceptible to bring even limited improvements, such as treatment with ALAnerv® seemed to have proven, is worth being surveyed, under strict circumstances of ethics and research methodology. Considering the necessity for more statistical power concerning primary, secondary end-points, and safety issues, as well, continuing this research is needed.

Abbreviations: SCI = spinal cord injury, TSCI = traumatic spinal cord injury, BBB = blood brain barrier, CNS = central nervous system, SC = spinal cord, NSAIDs = non-steroidal anti-inflammatory drugs, SAIDs = steroidal anti-inflammatory drugs, AIS = American Spinal Injury Association Impairment Scale, SPSS = Statistical Package for Social Sciences, BATEH = Bagdasar-Arseni Teaching Emergency Hospital

Keywords

About this article

PMC ID: 4556909
PubMed ID: 26351530
DOI: 

Article Publishing Date (print): Jul-Sep 2015
Available Online: 

Journal information

ISSN Printing: 1844-122X
ISSN Online: 1844-3117
Journal Title: Journal of Medicine and Life

Copyright License: Open Access

This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use and redistribution provided that the original author and source are credited.


SCImago Journal & Country Rank

Issues

Special Issues